MediSix Therapeutics
Founded Year
2016Stage
Series C | AliveTotal Raised
$62.86MLast Raised
$22.5M | 3 yrs agoAbout MediSix Therapeutics
MediSix Therapeutics develops cellular therapies to address T-cell malignancies. It provides a technology platform based on genetic engineering that focuses on the treatment of leukemias and lymphomas. The company was founded in 2016 and is based in Singapore.
Loading...
Loading...
MediSix Therapeutics Patents
MediSix Therapeutics has filed 2 patents.
The 3 most popular patent topics include:
- clusters of differentiation
- immune system
- immunology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/9/2018 | 5/16/2023 | Clusters of differentiation, Immunology, Immune system, T cells, Transcription factors | Grant |
Application Date | 8/9/2018 |
|---|---|
Grant Date | 5/16/2023 |
Title | |
Related Topics | Clusters of differentiation, Immunology, Immune system, T cells, Transcription factors |
Status | Grant |
Latest MediSix Therapeutics News
Apr 8, 2022
Twist Bioscience (Nasdaq: TWST) and MediSix Therapeutics have announced a collaboration to discover novel antibodies against five undisclosed targets. Under the terms of the collaboration, Twist will leverage its proprietary Library of Libraries to discover five novel antibodies directed against MediSix’s targets. MediSix will use its unique platform technologies to develop novel CAR T-cell therapies targeting malignancies and autoimmune… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login . If your trial has come to an end, you can subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK
MediSix Therapeutics Frequently Asked Questions (FAQ)
When was MediSix Therapeutics founded?
MediSix Therapeutics was founded in 2016.
What is MediSix Therapeutics's latest funding round?
MediSix Therapeutics's latest funding round is Series C.
How much did MediSix Therapeutics raise?
MediSix Therapeutics raised a total of $62.86M.
Who are the investors of MediSix Therapeutics?
Investors of MediSix Therapeutics include Osage University Partners, Advanced Technology Ventures, Lightstone Ventures, Three Arch Partners and Temasek.
Loading...
Loading...